These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 14989199)

  • 1. HIV treatment interruptions: a review.
    Newcomb-Fernandez J
    Res Initiat Treat Action; 2003; 9(2):5-13. PubMed ID: 14989199
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunological changes during treatment interruptions: risk factors and clinical sequelae.
    Poulton MB; Sabin CA; Fisher M
    AIDS; 2003 Jan; 17(1):126-8. PubMed ID: 12478080
    [No Abstract]   [Full Text] [Related]  

  • 3. [HIV-infection: modern antiretroviral therapy].
    Rockstroh JK; Spengler U
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1921-4. PubMed ID: 15372371
    [No Abstract]   [Full Text] [Related]  

  • 4. Stopping antiretroviral therapy in 'prematurely treated' HIV-1-infected children with full viral supression is safe.
    Reula ES; León-Leal JA; Leal M; Obando I; Muñoz-Fernández A
    AIDS; 2006 Jan; 20(2):307-9. PubMed ID: 16511434
    [No Abstract]   [Full Text] [Related]  

  • 5. When to start, when to STI (or, groping for the golden moment).
    Mascolini M
    IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
    Wit FW; Blanckenberg DH; Brinkman K; Prins JM; van der Ende ME; Schneider MM; Mulder JW; de Wolf F; Lange JM;
    AIDS; 2005 Feb; 19(3):345-8. PubMed ID: 15718848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV treatment series. Treatment interruptions. Reviewing what we've learned so far.
    Staszow K
    Posit Aware; 2006; 17(3):37-40. PubMed ID: 16791962
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trying to make sense of treatment interruptions.
    Lewis D; Sutton RE
    Res Initiat Treat Action; 2003; 9(2):14-5. PubMed ID: 14989200
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation and control of the human immunodeficiency virus.
    Stengel RF
    Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J; Hirschel B
    AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
    [No Abstract]   [Full Text] [Related]  

  • 15. Dynamics and evolution of HIV-1 during structured treatment interruptions.
    Frost SD
    AIDS Rev; 2002; 4(3):119-27. PubMed ID: 12416446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interruptions may be beneficial.
    AIDS Patient Care STDS; 2002 Oct; 16(10):512. PubMed ID: 12442736
    [No Abstract]   [Full Text] [Related]  

  • 17. Are short interruptions safe?
    Nagy GS
    AIDS Clin Care; 2002 May; 14(5):47. PubMed ID: 12004880
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection.
    Boschi A; Tinelli C; Ortolani P; Arlotti M
    J Antimicrob Chemother; 2006 Mar; 57(3):520-6. PubMed ID: 16387747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4 cell count-guided treatment interruption: be smart and wait for more evidence.
    Arduino R
    Clin Infect Dis; 2005 Mar; 40(5):735-7. PubMed ID: 15714421
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-HIV agents. Should HAART begin right after an HIV diagnosis?
    TreatmentUpdate; 2009; 21(3):2-3. PubMed ID: 19630120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.